|
Demographics
|
|
Age (years)
|
67
|
[12.5]
|
64
|
[11.5]
|
71
|
[18.5]
|
68
|
[8]
|
|
Sex (male)
|
52%
|
(30)
|
32%
|
(7)
|
68%
|
(15)
|
57%
|
(8)
|
|
Race (non-White)
|
63%
|
(36/57)
|
55%
|
(12)
|
55%
|
12
|
92%
|
(12)
|
|
BMI (kg/m2)
|
27.6
|
[7.9]
|
26.1
|
[5.3]
|
28.2
|
[10.2]
|
29.5
|
[9.9]
|
|
Obesity (BMI > 30 kg/m2)
|
37%
|
(21/57)
|
27%
|
(6)
|
38%
|
(8/21)
|
50%
|
(7)
|
|
Comorbidities
|
|
High cardiovascular risk profile (≥ 2 of hypertension, hyperlipidemia, diabetes)
|
55%
|
(32)
|
36%
|
(8)
|
64%
|
(14)
|
71%
|
(10)
|
|
Hypertension
|
64%
|
(37)
|
59%
|
(13)
|
59%
|
(13)
|
79%
|
(11)
|
|
Hyperlipidemia
|
62%
|
(36)
|
50%
|
(11)
|
59%
|
(13)
|
86%
|
(12)
|
|
Diabetes
|
28%
|
(16)
|
9%
|
(2)
|
45%
|
(10)
|
29%
|
(4)
|
|
Previous atherosclerotic complications (CAD and/or CVA)
|
22%
|
(13)
|
0%
|
(0)
|
36%
|
(8)
|
36%
|
(5)
|
|
Congestive heart failure
|
12%
|
(7)
|
0%
|
(0)
|
14%
|
(3)
|
29%
|
(4)
|
|
Current or former smoker
|
37%
|
(21/57)
|
27%
|
(6)
|
38%
|
(8/21)
|
50%
|
(7)
|
|
Lung disease (COPD, emphysema, asthma, bronchiectasis)
|
21%
|
(12)
|
18%
|
(4)
|
27%
|
(6)
|
14%
|
(2)
|
|
Chronic kidney disease (eGFR < 60 mL/min)
|
24%
|
(14)
|
23%
|
(5)
|
27%
|
(6)
|
21%
|
(3)
|
|
History of other malignancy
|
9%
|
(5)
|
5%
|
(1)
|
5%
|
(1)
|
21%
|
(3)
|
|
Number of comorbidities
|
2
|
[3]
|
1
|
[1.75]
|
3
|
[3]
|
3.5
|
[1.75]
|
|
Concomitant medication
|
|
Anticoagulation
|
21%
|
(12)
|
9%
|
(2)
|
27%
|
(6)
|
29%
|
(4)
|
|
Aspirin
|
59%
|
(34)
|
59%
|
(13)
|
59%
|
(13)
|
57%
|
(8)
|
|
Statin
|
47%
|
(27)
|
14%
|
(3)
|
59%
|
(13)
|
79%
|
(11)
|
|
ACE inhibitor or angiotensin II receptor blocker
|
45%
|
(26)
|
36%
|
(8)
|
41%
|
(9)
|
64%
|
(9)
|
|
Beta blocker
|
34%
|
(20)
|
9%
|
(2)
|
50%
|
(11)
|
50%
|
(7)
|
|
Metformin
|
16%
|
(9)
|
5%
|
(1)
|
32%
|
(7)
|
7%
|
(1)
|
|
Non-steroidal anti-inflammatory drug
|
5%
|
(3)
|
5%
|
(1)
|
5%
|
(1)
|
7%
|
(1)
|
|
Oral corticosteroids
|
53%
|
(31)
|
45%
|
(10)
|
50%
|
(11)
|
71%
|
(10)
|
|
COVID-19 confirmed by PCR at MSH
|
71%
|
(41)
|
59%
|
(13)
|
86%
|
(19)
|
64%
|
(9)
|
